Ozempic Litigation Update 2026: The Critical Shift to Objective Proof

As of February 2026, the Ozempic litigation (MDL 3094 and the newly formed NAION-specific MDL 3163) has shifted from general “failure to warn” claims to a rigorous, evidence-based phase.

1. Gastroparesis: The “Gold Standard” Requirement

Judge Karen Marston issued a critical ruling in late 2025 requiring all plaintiffs claiming gastroparesis (stomach paralysis) to provide objective medical testing. Subjective symptoms like nausea or “feeling full” are no longer sufficient to maintain a claim in the MDL.

• Primary Test: Gastric Emptying Study (Scintigraphy): This is the “Gold Standard.” A patient eats a meal tagged with a tiny amount of radioactive material, and a camera tracks how quickly it leaves the stomach.
• Alternative Tests: The court also accepts Wireless Motility Capsules (SmartPill) or 13C-Spirulina Breath Tests.
• Excluded Evidence: CT scans, MRIs, and endoscopies are generally insufficient because they can rule out obstructions but cannot measure the actual speed of stomach motility.
• Clinical Threshold: Most firms now require a diagnosis confirming delayed emptying while the patient was actively using the medication or within 30 days of stopping.

2. NAION (Vision Loss): The New “High-Value” Track

In December 2025, a separate multidistrict litigation (MDL 3163) was created specifically for vision loss claims. Because NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) is a permanent injury, these cases often carry higher valuation than gastrointestinal claims.

• Diagnostic Criteria: A formal diagnosis of NAION by an Ophthalmologist or Neuro-Ophthalmologist is mandatory.
• Clinical Signs: Documentation must show sudden, painless vision loss (often upon waking), “optic disc swelling” (edema), and specific visual field defects.
• Exclusion of Mimics: Records must rule out “Giant Cell Arteritis” or “Optic Neuritis” to ensure the injury is vascular in nature, as linked to semaglutide in recent studies.

3. Why Mohr Marketing’s AI WebTracker® is Relevant Now

With these strict 2026 court standards, the “spray and pray” lead generation of previous years has become obsolete. Mohr Marketing’s AI WebTracker® is being used by law firms to:

• As the cost-per-signed-case for GLP-1 litigation continues to rise, Mohr Marketing, LLC is setting a new industry standard for lead integrity. Unlike traditional marketing agencies that rely on broad-net social media forms, Mohr Marketing utilizes its proprietary AI WebTracker® technology to identify and engage high-intent claimants through behavior-based data points.

• Causation Mapping: Use AI to cross-reference the date of first semaglutide use with the date of first medical complaint, ensuring the “temporal relationship” required by the court.
• Scammer Scrub™: Eliminating the high volume of fraudulent leads that plagued early Ozempic filings.

Litigation Snapshot (Feb 2026)

Contact Mohr Marketing today to secure your exclusive, signed GLP-1 retainers and build a cleaner, more valuable docket.

Contact Mohr Marketing today to discuss our GLP-1 Availability.

Ready to fill your docket with valid cases?

Partner with Mohr Marketing to secure high-quality, compliant plaintiffs.

Contact Mohr Marketing to deploy the Compliance Shield today.

Click Here Get a Custom Quote

Let’s discuss your specific needs and how our Compliance Program, AI Lead Generation Technology, digital marketing, and mass tort cases can help you achieve your growth goals.

www.mohrmktg.com 

Mohr Marketing Team

Summary

Article Name

The 2026 Ozempic Litigation Pivot: From Symptoms to Scintigraphy

Description

2026 Ozempic Update: MDL 3094 mandates objective proof for Gastroparesis & NAION. Use AI WebTracker® to find high-intent claimants meeting the new Gold Standard.

Author

Mohr Marketing Team

Publisher Name

Mohr Marketing, LLC

Publisher Logo